Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus bevacizumab biosimilar for recurrent or metastatic hepatocellular carcinoma after surgery or local treatment
ChiCTR2100042487Phase 4Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Overall survival. Started Feb 2021; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100042487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042487.